Stay updated on TheraSphere in Inoperable Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the TheraSphere in Inoperable Liver Cancer Clinical Trial page.

Latest updates to the TheraSphere in Inoperable Liver Cancer Clinical Trial page
- Check4 days agoChange DetectedThe footer’s site revision changes from v3.7.0 to v3.7.1, while the study-record page remains a 403 Forbidden error.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content, reflecting an access restriction. This change affects what users can view on the page but does not constitute a substantive update to the study information.SummaryDifference17%

- Check46 days agoChange DetectedThe page's revision identifier was updated from v3.6.5 to v3.6.6, indicating an internal update to the page template. This does not alter the study details or data presented on the page.SummaryDifference0.0%

- Check67 days agoChange DetectedThe site's revision tag was updated from Revision: v3.6.4 to Revision: v3.6.5, indicating a new deployment of the interface. This reflects the version of the ClinicalTrials.gov site rather than any change to the study record.SummaryDifference0.0%

- Check82 days agoChange DetectedA new site revision tag, Revision: v3.6.4, was added replacing Revision: v3.6.3, indicating a minor build update. The change does not modify the study details or the information presented to users.SummaryDifference0.0%

- Check103 days agoChange DetectedThe page revision was incremented from v3.6.2 to v3.6.3, indicating a minor update to the page metadata. This change does not modify study data, eligibility criteria, or reported results.SummaryDifference0.0%

Stay in the know with updates to TheraSphere in Inoperable Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TheraSphere in Inoperable Liver Cancer Clinical Trial page.